Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Br J Dermatol. 2022 Sep;187(3):438-441. doi: 10.1111/bjd.21233. Epub 2022 Jun 7.

Abstract

Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.

Publication types

  • Clinical Trial, Phase III
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic* / complications
  • Arthritis, Psoriatic* / drug therapy
  • Humans
  • Nail Diseases* / complications
  • Nail Diseases* / etiology
  • Nails, Malformed*
  • Psoriasis* / complications
  • Psoriasis* / drug therapy
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • secukinumab

Grants and funding